Metformin remains the standard first-line medication for type 2 diabetes. Newer classes — SGLT2 inhibitors (Jardiance, Farxiga) and GLP-1 agonists (Ozempic, Trulicity) — offer blood sugar control plus proven heart and kidney protection. Each class lowers blood sugar through a completely different mechanism, and many patients ultimately use two or more.
Medications for Type 2 Diabetes: A Plain-English Guide
Type 2 diabetes is a condition in which the body either does not produce enough insulin or does not use it effectively, resulting in elevated blood glucose. Left uncontrolled, high blood sugar damages blood vessels, nerves, kidneys, and eyes over time. Medication is usually part of management alongside lifestyle changes — and the pharmacological toolkit for type 2 diabetes has expanded dramatically in the past decade with new drug classes that do more than just lower blood sugar.
This guide explains the major drug classes used in type 2 diabetes treatment, how each one works at the physiological level, and what drives clinical decisions about which to use. The goal is to help patients understand what their medications are actually doing — and why their doctor may be managing their diabetes differently than someone else they know.
Drug Classes Used for Type 2 Diabetes
Metformin is the universally recommended first-line medication for type 2 diabetes and has been so for decades. It primarily works by reducing the amount of glucose the liver releases into the bloodstream overnight and between meals — addressing one of the core problems in type 2 diabetes. It also modestly improves insulin sensitivity in muscle tissue. Metformin does not cause hypoglycemia (low blood sugar) on its own and is associated with modest weight neutrality or slight weight loss. It is inexpensive, well-studied, and carries a strong long-term safety record. The main drawback is GI side effects — nausea, diarrhea — which are common early on but often improve over time or with extended-release formulations.
SGLT2 inhibitors work in the kidneys. Normally, the kidneys filter blood glucose and reabsorb nearly all of it back into the bloodstream. SGLT2 inhibitors block the transporter responsible for this reabsorption, causing excess glucose to be excreted in urine. This lowers blood sugar without depending on insulin at all. Beyond glucose control, SGLT2 inhibitors have demonstrated significant cardiovascular and kidney-protective benefits in large clinical trials — they reduce hospitalizations for heart failure and slow the progression of diabetic kidney disease. These benefits have made them a preferred add-on in patients with established heart disease or chronic kidney disease. A common side effect is genital yeast infections due to the increased glucose in the urinary tract.
GLP-1 receptor agonists mimic glucagon-like peptide 1, a hormone released by the gut after eating. GLP-1 stimulates the pancreas to release insulin only when blood sugar is elevated (so the risk of hypoglycemia is low), suppresses the release of glucagon (which raises blood sugar), slows stomach emptying, and reduces appetite. The appetite suppression effect produces significant weight loss, making this class especially valuable in patients with obesity and type 2 diabetes. Like SGLT2 inhibitors, several GLP-1 agonists have demonstrated cardiovascular benefits in outcomes trials. Most are injectable (once weekly or daily), though oral semaglutide (Rybelsus) is available.
DPP-4 inhibitors work by blocking the enzyme that breaks down GLP-1 and other incretin hormones, thereby prolonging their natural effect. The result is a modest increase in insulin secretion after meals and a reduction in glucagon. Their blood sugar-lowering effect is less powerful than GLP-1 agonists or SGLT2 inhibitors, but they are well-tolerated, weight-neutral, and do not cause hypoglycemia. They are oral medications taken once daily and are a reasonable choice when tolerability is the primary concern, though they lack the cardiovascular and renal benefit data of the newer classes.
Sulfonylureas stimulate the pancreas to produce more insulin, regardless of blood glucose levels. They are effective, inexpensive, and have been used for over 60 years. The significant downside is hypoglycemia risk — because insulin release is not glucose-dependent, blood sugar can drop too low, particularly if a meal is skipped. Weight gain is also a common effect. While still widely used given their low cost, sulfonylureas are less favored in newer guidelines when patients have access to SGLT2 inhibitors or GLP-1 agonists that offer additional benefits without the hypoglycemia risk.
Insulin is the most potent glucose-lowering medication available and can be used at any stage of type 2 diabetes. There are multiple types: long-acting (basal) insulins given once daily to control fasting glucose, and rapid-acting insulins given at meals to handle the glucose spike from food. Some patients use both. Insulin does not fail — if blood sugar remains high, the amount can be adjusted. The main challenges are hypoglycemia risk, weight gain, and the requirement for injection. Insulin pens have made administration much simpler than older syringe-based approaches.
How Doctors Choose Which Medication
Metformin is the starting point for almost everyone with type 2 diabetes who can tolerate it, often added at or shortly after diagnosis. When blood sugar control is insufficient on metformin alone, a second agent is added based on clinical priorities. For patients with established cardiovascular disease or high cardiovascular risk, an SGLT2 inhibitor or GLP-1 agonist with proven cardiovascular outcomes data is now strongly recommended by major guidelines (ADA, ACC). For patients with obesity as a major driver, a GLP-1 agonist is often preferred due to its appetite-suppressing effects. For patients with chronic kidney disease, both SGLT2 inhibitors and certain GLP-1 agonists have kidney-protective evidence.
Cost is a real factor. Metformin and sulfonylureas are inexpensive generics. SGLT2 inhibitors and GLP-1 agonists are expensive, though insurance coverage has improved. DPP-4 inhibitors fall in between. A treatment plan that is affordable and maintainable is always preferable to an optimal plan a patient cannot afford to follow.
Frequently Asked Questions
Is metformin safe for everyone with type 2 diabetes?
Metformin is safe for most people but is contraindicated when kidney function is severely reduced, due to a rare risk of lactic acidosis. It is also typically held before imaging procedures using iodinated contrast dye. GI side effects (nausea, diarrhea) are common initially and often improve with time or when switching to extended-release formulations.
What is the difference between Ozempic and Jardiance?
Ozempic (semaglutide) is a GLP-1 receptor agonist — it mimics an incretin gut hormone to stimulate insulin release and suppress glucagon, with significant weight loss effects. Jardiance (empagliflozin) is an SGLT2 inhibitor — it blocks glucose reabsorption in the kidney, excreting it in urine. Both have cardiovascular and kidney-protective benefits beyond blood sugar control but through completely different mechanisms. They can be used together.
Does needing insulin mean you've failed at managing diabetes?
Absolutely not. Type 2 diabetes is a progressive condition; the insulin-secreting cells of the pancreas naturally decline in function over time, often regardless of lifestyle and medication adherence. Needing insulin later in the course of type 2 diabetes reflects disease progression, not personal failure. Many people with well-managed diabetes eventually need insulin, and starting it often brings significant relief from symptoms of poor blood sugar control.
Need to identify a pill by its imprint, shape, or color?
Use the PillID Pill Identifier →